乐观
$44.66
情景价格
$59.750
-0.807 (-1.35%)收盘时
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.
Jefferies
$76
2026-10-12
Jefferies
2026-10-12
目标价
$76
William Blair
—
2026-10-12
William Blair
2026-10-12
目标价
—
BofA
$66
2026-10-09
BofA
2026-10-09
目标价
$66
Cantor Fitzgerald
$53
2026-10-08
Cantor Fitzgerald
2026-10-08
目标价
$53
Morgan Stanley
$41
2026-10-07
Morgan Stanley
2026-10-07
目标价
$41
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

BioNTech Faces Setbacks in Clinical Trials Amid Pipeline Hopes

Investment Choice: Bristol-Myers Squibb vs. Johnson & Johnson

Investment Choices: Bristol Myers Squibb vs. Eli Lilly

Bristol Myers Squibb's Mixed Results in Lung Disease Trials

Bristol Myers Squibb Reports Positive ACTION-1 Trial Results
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.
22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.


Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
展开
$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.
展开本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。